Why Are Successful Scientists Leaving Academia Mid-Career?
Three researchers who left academia share their tales of self discovery, course correction, and growth.
Related Articles
What are the Horn and Halo Effects?
Tl;dr: The Horn and Halo Effects are cognitive biases where our first impression influences our decision making and how we feel about someone.
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for
On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or…
Fructose Hijacks the Liver to Grow Cancer
New data in Nature reveal how Fructose can Fuel Cancer. The mechanism is shocking, and sneaky. Basically, cancer can hijack your liver to turn fructose…
Oregon house cat died after eating pet food that tested positive for bird flu
Oregon authorities say a house cat died after eating raw frozen pet food that tested positive for bird flu.
TheEVIDENCEis in
Anticancer living is built on a belief that self-care is health care and that greater wellness is available to us all. Introducing the concept of…
Chronological versus immunological aging: Immune rejuvenation to arrest cognitive decline
Basurco and Abellanas et al. discuss how immune system aging negatively impacts the brain and propose immune rejuvenation as a strategy to combat cognitive decline and…
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein
The rearranged-during-transfection (RET) kinase is a validated target for the treatment of RET-altered cancers. Currently approved RET-selective kinase inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), increase…
Thrombosis and Hemostasis Conference | ISTH 2025 Congress
The ISTH 2025 Congress is the premier international medical and scientific conference for experts in the fields of thrombosis, hemostasis and vascular biology. Join us…
Survival in Patients With Hematologic Cancers and COVID-19
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
